Pfizer Submits IND Application in China for TYK2 Inhibitor PF-06826647

By Baihuawen

On April 20, the clinical trial application for Pfizer’s TYK2 inhibitor PF-06826647 tablets submitted in China was accepted by the Center for Drug Evaluation (CDE). This drug is currently in Phase I/II clinical trials globally.

Tyk2 is a non-receptor tyrosine kinase that mediates immune signaling. Tyk2 primarily mediates signaling pathways driven by IL-23, IL-12, and type I interferons, but does not mediate cytokine responses driven by other kinases (such as those involved in IL-6, hematopoietic growth factor, and IL-2 family signaling). Tyk2 signaling is involved in the pathophysiology of various immune-related diseases, such as psoriasis, lupus, and inflammatory bowel disease.

No Tyk2 inhibitors have been approved for marketing worldwide to date. The most advanced candidate in this class, BMS-986165, has entered Phase III clinical trials and has received approval for three clinical trials in China, targeting plaque psoriasis, Crohn’s disease, and lupus nephritis (see: “Third Clinical Trial Approved in China for Novel Anti-inflammatory TYK2 Inhibitor, for the Treatment of Lupus Nephritis”).

Pfizer’s JAK1/Tyk2 inhibitor PF-06700841 has been approved for clinical trials in China for the treatment of systemic lupus erythematosus. Domestic companies developing drugs of this class include InnoCare Pharma (ICP-330).

PharmaCube NextPharma